Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sex differences have been described in diabetes cardiovascular outcome trials (CVOTs). PURPOSE: We systematically reviewed for baseline sex differences in cardiovascular (CV) risk factors and CV protection therapy in diabetes CVOTs. DATA SOURCES: Randomized placebo-controlled trials examining the effect of diabetes medications on major adverse cardiovascular events in people ≥18 years of age with type 2 diabetes. STUDY SELECTION: Included trials reported baseline sex-specific CV risks and use of CV protection therapy. DATA EXTRACTION: Two reviewers independently abstracted study data. DATA SYNTHESIS: We included five CVOTs with 46,606 participants. We summarized sex-specific data using mean differences (MDs) and relative risks (RRs) and pooled estimates using random effects meta-analysis. There were fewer women than men in included trials (28.5–35.8% women). Women more often had stroke (RR 1.28; 95% CI 1.09, 1.50), heart failure (RR 1.30; 95% CI 1.21,1.40), and chronic kidney disease (RR 1.33; 95% CI 1.17; 1.51). They less often used statins (RR 0.90; 95% CI 0.86, 0.93), aspirin (RR 0.82; 95% CI 0.71, 0.95), and β-blockers (RR 0.93; 95% CI 0.88, 0.97) and had a higher systolic blood pressure (MD 1.66 mmHg; 95% CI 0.90, 2.41), LDL cholesterol (MD 0.34 mmol/L; 95% CI 0.29, 0.39), and hemoglobin A1c (MD 0.11%; 95% CI 0.09, 0.14 [1.2 mmol/mol; 1.0, 1.5]) than men. LIMITATIONS: We could not carry out subgroup analyses due to the small number of studies. Our study is not generalizable to low CV risk groups nor to patients in routine care. CONCLUSIONS: There were baseline sex disparities in diabetes CVOTs. We suggest efforts to recruit women into trials and promote CV management across the sexes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Despite this, women have been underrepresented in recent CVOTs in diabetes, comprising between 28.5 and 35.8% of participants (287).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Self-citationLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Research works printed but not linked: 1
- Diabetes Canada . Cardiovascular protection in people with diabetes. Accessed 27 December 2019. Available from https://www.diabetes.ca/health-care-providers/clinical-practice-guidelines/chapter-23#panel-tab_Recommendations
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
“This analysis also described differing patterns of cardiovascular complications in women compared with men, and poorer management of cardiovascular risk factors in women [287].”
Sex differences in type 2 diabetes
Kautzky-Willer, A., Leutner, M., & Harreiter, J. (2023) · Diabetologia · doi:10.1007/s00125-023-05891-x · Cited by 624
“Therefore, regardless of their comorbidities, fewer women with type 2 diabetes were treated in accordance with the guidelines than men [70].”
BackgroundGender-Related Factors in Medication Adherence for Metabolic and Cardiovascular Health
Venditti, V., Bleve, E., Morano, S., & Filardi, T. (2023) · Metabolites · doi:10.3390/metabo13101087 · Cited by 134
“However, current studies about treatment outcomes between men and women still lack good female representation and are therefore unreliable [30,31].”
BackgroundAge and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis
Hanlon, P., Butterly, E. W., Wei, L. S., Wightman, H., Almazam, S. A., Alsallumi, K., Crowther, J., McChrystal, R., Rennison, H., Hughes, K., et al. (2025) · JAMA · doi:10.1001/jama.2024.27402 · Cited by 61
“3,18 We aimed to perform a systematic review and meta-analysis of both aggregate and individual participant trial data to estimate whether the efficacy of SGL2i, GLP1ra and DPP4i therapy for type 2 diabetes differs by age and sex.”
Verhagen, C., Janssen, J., Biessels, G. J., Johansen, O. E., & Exalto, L. G. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.10.013 · Cited by 48
Do sex differences in paediatric type 1 diabetes care exist? A systematic review
de Vries, S. A. G., Verheugt, C. L., Mul, D., Nieuwdorp, M., & Sas, T. (2023) · Diabetologia · doi:10.1007/s00125-022-05866-4 · Cited by 48
Harreiter, J., Fadl, H., Kautzky‐Willer, A., & Simmons, D. S. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01348-2 · Cited by 47
McClements, L., Kautzky‐Willer, A., Kararigas, G., Ahmed, S. B., & Stallone, J. N. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00714-7 · Cited by 52
“Moreover women remain undertreated and less often attain their target values of important risk factors like LDL cholesterol, blood pressure, or HbA1c in many studies [63, 77].”
Broni, E. K., Ndumele, C. E., Echouffo-Tcheugui, J. B., Kalyani, R. R., Bennett, W. L., & Michos, E. D. (2022) · Current Diabetes Reports · doi:10.1007/s11892-021-01444-x · Cited by 35
Gisinger, T., Azizi, Z., Alipour, P., Harreiter, J., Raparelli, V., Kublickiene, K. R., Herrero, M. T., Norris, C. M., Emam, K. E., Pilote, L., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1090541 · Cited by 35
Zhang, J., Jin, Y., Jia, P., Li, N., & Zheng, Z. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910389 · Cited by 34
“undertreated, and underreported in women [9,10] and that they do not receive proper preventive measures [8,11].”
BackgroundAnalysis of Gender-Based Inequality in Cardiovascular Health: An Umbrella Review
Bosomworth, J., & Khan, Z. U. (2023) · Cureus · doi:10.7759/cureus.43482 · Cited by 34
“also acknowledge that women with type 1 and type 2 diabetes are known to have a higher risk of CVD, stroke, heart failure, and mortality when compared to men [33].”
BackgroundWebb, J., Mount, J., von Arx, L., Rachman, J., Spanopoulos, D., Wood, R. P., Tritton, T., Massey, O., & IDRIS, I. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14580 · Cited by 24
Kautzky‐Willer, A., Leutner, M., Abrahamian, H., Frühwald, L., Hoppichler, F., Lechleitner, M., & Harreiter, J. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02185-5 · Cited by 24
Mousavi, S., Greenberg, D. T., Ndjaboué, R., Greiver, M., Drescher, O., Dansokho, S. C., Boutin, D., Chouinard, J.-M., Dostie, S., Fenton, R., et al. (2023) · JMIR Diabetes · doi:10.2196/35682 · Cited by 23
Challenges in Optimizing Lipid Management in Women
Peterson, K., Kaur, G., Gianos, E., Mookherjee, S., Poli, K. A., Sidhu, M. S., & Lyubarova, R. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07273-0 · Cited by 20
Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved?
Siostrzonek, P., Brath, H., Zweiker, R., Drexel, H., Hoelzl, R., Hemetsberger, M., & Ray, K. K. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01978-w · Cited by 15
Chen, T., Wang, Y., Li, X., Feng, J., Yang, H., Li, Y., Feng, H., & Xiao, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-42247-2 · Cited by 13
Ferrannini, G., Maldonado, J. M., Raha, S., Ps, R., Khatun, R., Atisso, C. M., Shurzinske, L., Gerstein, H. C., Rydén, L., & Bethel, M. A. (2023) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2023.2166101 · Cited by 17
“…percentage of women using cardiovascular protective medications such as ACE inhibitors (49% vs. 55%), statins (73% vs. 83%), and aspirin (72% vs. 81%), and data from a systematic review and meta-analysis [21] of five CVOTs in diabetes showing that fewer women used statins, beta-blockers or aspirin.”
BackgroundSex, Gender, and Cardiovascular Disease in Chronic Kidney Disease
Yi, T. W., & Levin, A. (2022) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2022.04.009 · Cited by 16
Kohansal, K., Masrouri, S., Khalili, D., Ramezankhani, A., Azizi, F., Blaha, M. J., & Hadaegh, F. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01709-z · Cited by 13
“Previous studies suggest that T2DM is a more decisive risk factor for vascular disease and mortality in women than in men [13, 14].”
BackgroundLeBlanc, E. S., Brooks, N., Davies, M., & Chatterjee, R. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae655 · Cited by 11
Minutolo, R., Simeon, V., Nicola, L. D., Chiodini, P., Galiero, R., Rinaldi, L., Caturano, A., Vetrano, E., Sardu, C., Marfella, R., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02371-3 · Cited by 12
“Indeed, women are currently less likely than men to receive an extensive cardioprotective treatment including statins, aspirin, beta blockers, sodium–glucose cotransporter 2 inhibitors (SGLT2i) or GLP-1 receptor agonists (GLP-1RA) [9, 11, 12].”
BackgroundArcopinto, M., Valente, V., Giardino, F., Marra, A. M., & Cittadini, A. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-03019-4 · Cited by 14
“A meta-analysis involving > 40,000 participants with T2DM from five studies [10] showed a significant underrepresentation of women in these trials (28.”
Sciannameo, V., Berchialla, P., Avogaro, A., Fadini, G. P., DARWIN-T2D Network, Consoli, A., Formoso, G., Grossi, G., Pucci, A., Sesti, G., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01300-y · Cited by 10
“Other remarkable differences have been highlighted between CVOT populations and the typical outpatients with T2D, including age and sex distribution [11].”
BackgroundCROMER, S. J., Thaweethai, T., & Wexler, D. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05997-2 · Cited by 8
Zhou, Z., Huang, Y., Zhuang, X., Guo, Y., Xie, P., Xiong, Z., Liu, M., Zhang, W., Zhong, J., Li, Y., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.034626 · Cited by 11
“41 Another popular belief is that changes in sex hormone concentrations are involved in the pathogenesis of CAN; however, further research is needed to confirm this.”
Opportunities To Improve Diabetes Care in the Hemodialysis Unit: A Cohort Study in Ontario, Canada
Clemens, K. K., Ouédraogo, A. M., Garg, A. X., Silver, S. A., & Nash, D. M. (2021) · Kidney360 · doi:10.34067/kid.0007082020 · Cited by 9
Self-citationPujante, P., Torre, E. L. M., Morales-Sánchez, P., Escobedo, R. R., Barreiro, S. C., Rojo‐Martínez, G., & Delgado, E. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2020.12.040 · Cited by 8
Al‐Salameh, A., Bouzegaoui, N. E., & Saraval, M. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.09.023 · Cited by 14
Green, J. B., Merrill, P., Lokhnygina, Y. V., Mentz, R. J., Alfredsson, J., Holman, R. R., & the EXSCEL Study Group (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14993 · Cited by 7
“A majority were men; however, 38% female participants compares favourably with many recent CVOTs in diabetes.(34) In addition, women enrolled in EXSCEL were more diverse with respect to race, ethnicity and region than were men.”
Resultde Groen, P., Blok, L. C. H. M., Snethlage, C. M. F., Hanssen, N. M. J., Rampanelli, E., & Nieuwdorp, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110788 · Cited by 6
“…repercussions accompanying deregulated insulin secretion extend beyond hyperglycemia and accelerate cardiovascular disease, resulting in a five-times elevated risk of developing cardiovascular events and increased cardiovascular and all-cause mortality, with a reduced lifespan of 13 years [5–7].”
Holland, D., Fryer, A. A., Stedman, M., Hanna, F., Duff, C. J., Green, L., Scargill, J., Halsall, I., Gaskell, N., Howe, J. D., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01482-6 · Cited by 9
“In addition, compliance to medication or prescription treating cardiovascular risk factors is lower in women than men with diabetes mellitus, with less use of statins, aspirin and beta blockers [43].”
BackgroundMattsson, K., Pihlsgård, M., Enhörning, S., & Timpka, S. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.22081 · Cited by 7
Rai, S. K., Choi, H. K., Lu, N., Yokose, C., Lin, K., Lee, D. H., Tabung, F. K., & McCormick, N. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43127 · Cited by 6
“24,25 Such health disparities for women are not unique to gout, 26,27 and increasing recognition of this persistent health gap has catalyzed national and global efforts to improve health equity for women, including the White House Initiative on Women ’ s Health Research 28 and the World Economic…”
Iveljić, I., Young, M., Corhodzic, E., Cullen, F., Prag, H. A., Murphy, M. P., & Aksentijević, D. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02771-z · Cited by 5
Hofer-Zeni, S., Leutner, M., Klimek, P., Bellach, L., Pávó, N., Prausmüller, S., Hülsmann, M., & Kautzky‐Willer, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02360-6 · Cited by 7
“In agreement with other studies, significantly higher HbA1c and LDL levels in female patients of this study population might also point out an under-treatment for diabetes and cardiovascular diseases in women [56, 57].”
ResultSex Differences in the Relationship Between Lipid Ratios and the Risk of Carotid Plaque
Wang, L.-L., Xu, Z.-X., Sun, B., Liu, J., Liu, X.-L., & Liu, D. (2025) · Angiology · doi:10.1177/00033197251316624 · Cited by 6
Ang, S. H., Lim, L., Mustapha, F. I., Ahmad, E., & Rampal, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111976 · Cited by 4
Pujante, P., Torre, E. L. M., Morales-Sánchez, P., Escobedo, R. R., Barreiro, S. C., Rojo‐Martínez, G., & Delgado, E. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.12.040 · Cited by 5
Intersectoral action to transform health equity for women and girls globally
Sarri, G., Gabarró, M. S., Cheng, R.-F. J., & Jhutti-Johal, J. (2025) · Communications Medicine · doi:10.1038/s43856-025-01290-y · Cited by 5
Reyes‐García, R., Moreno, Ó., Guillen-Morote, C., Pardo, I. M., Doulatram‐Gamgaram, V. K., Cases, C. C., Mendoza, N. A., Pérez, C. T., Cárdenas‐Salas, J., Martínez‐Fuster, S., et al. (2025) · Nutrients · doi:10.3390/nu17142349 · Cited by 4
Representation of women in randomized controlled trials of novel antidiabetic drugs: A cohort study
Aharon‐Hananel, G., Cohen, Y., & Tau, N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15942 · Cited by 2
Sex dependent differences in oxidative stress in the heart of rats with type 2 diabetes
Горбенко, Н. И., Borikov, O. Y., Ivanova, O., Kiprych, T., Таран, Е. В., Gopciy, T. I., & Litvinova, Т. S. (2021) · The Ukrainian Biochemical Journal · doi:10.15407/ubj93.03.075 · Cited by 2
“However, when women are diagnosed with diabetes, this protective factor is disappeared as shown by a recent meta-analysis that concluded that women with diabetes have a 40% increased risk of developing CHD compared to men [5].”
Hanlon, P., Butterly, E. W., Wei, L., Wightman, H., Almazam, S. A., Alsallumi, K., Crowther, J., McChrystal, R., Rennison, H., Hughes, K., et al. (2024) · medRxiv · doi:10.1101/2024.06.23.24309242 · Cited by 2
Wang, J., Yan, W., Shi, K., Xu, H., Yu, S., Guo, Y., Jiang, L., Gao, Y., Yu-Jiang, Li, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02755-z · Cited by 1
Wang, M., Zhang, W., Li, J., Luan, Y., Ding, X., & Hu, Y. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04972-6 · Cited by 1
Koren, R., Elkan, M., Barouch, A., & Ziv‐Baran, T. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04170-4 · Cited by 2
“Yet, women used statins less often than men (RR 0.90; 95% CI 0.86, 0.93) [10].”
InfluentialLin, D. S., Lo, H.-Y., Huang, K.-C., Lin, T., Huang, C.-Y., Lee, J.-K., & Lin, L. (2026) · European journal of medical research · doi:10.1186/s40001-026-03849-4 · Cited by 1
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Impact of Sex and Gender Differences on Heart Failure, Especially in Elderly Patients
Cocco, G., Hofmann, H. P., & Pandolfi, S. (2024) · OBM Geriatrics · doi:10.21926/obm.geriatr.2401273 · Cited by 2
Clemens, K. K., & Ahmed, S. B. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.07.002 · Cited by 2
Self-citationMousavi, S., Greenberg, D. T., Ndjaboué, R., Greiver, M., Drescher, O., Dansokho, S. C., Boutin, D., Chouinard, J.-M., Dostie, S., Fenton, R., et al. (2021) · medRxiv · doi:10.1101/2021.12.14.21267759
Typ-2-Diabetes: geschlechterspezifische Unterschiede in Studienpopulationen
(2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1217-3056
Kohansal, K., Masrouri, S., Khalili, D., Ramezankhani, A., Azizi, F., Blaha, M. J., & Hadaegh, F. (2022) · Research Square · doi:10.21203/rs.3.rs-2030138/v1
Frantsiyants, E. M., Bandovkina, V., Kaplieva, I. V., Surikova, E. I., Neskubina, I. V., Trepitaki, L. K., Cheryarina, N. D., Pogorelova, Y., Kachesova, P. S., Goroshinskaya, I. A., et al. (2022) · Crimea Journal of Experimental and Clinical Medicine · doi:10.29039/2224-6444-2021-11-3-48-55
Kohansal, K., Masrouri, S., Khalili, D., Ramezankhani, A., Azizi, F., Blaha, M. J., & Hadaegh, F. (2022) · Research Square · doi:10.21203/rs.3.rs-2030138/v2
Effect of Gender on the Outcome of Acute Coronary Syndrome in Type 2 Diabetes Mellitus
Mahmood, A., Khan, K. U., Iqbal, M., Khan, J. A., Shah, S. A., & Khan, N. A. (2023) · Journal of Gandhara Medical and Dental Science · doi:10.37762/jgmds.10-3.451
Deischinger, C., Harreiter, J., & Kautzky‐Willer, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65952-2_6
Gender Matters: On Recurrence Risk of Cardiovascular Complications for Type 2 Diabetes SubjectsPreprint
Gentili, M., Leonardi, S., Silvestri, F., Croce, F., Rosati, R., Grani, G., Candido, R., Cianni, G. D., Mannino, D., Ponzani, P., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4902571/v1
Iveljić, I., Young, M., Corhodzic, E., Cullen, F., Prag, H. A., Murphy, M. P., & Aksentijević, D. (2025) · medRxiv · doi:10.1101/2025.04.14.25325801
Sciannameo, V., Berchialla, P., Avogaro, A., & Fadini, G. P. (2021) · Figshare · doi:10.6084/m9.figshare.14570234
Hofer-Zeni, S., Leutner, M., Klimek, P., Bellach, L., Pavo, N., Prausmüller, S., Hülsmann, M., & Kautzky‐Willer, A. (2024) · Figshare · doi:10.6084/m9.figshare.26756944
Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
Newman, C. B., Saunders, K. H., Schmitz, S. H., & Subramanian, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26712-3.00020-3
Egede, L. E., Walker, R. J., & Williams, J. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00026-4
Lee, C. C., & Liu, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45863-7.00086-x
Global barriers to GLP-1 receptor agonist treatment in women: access, safety, and equity
Meek, C. L., Anjana, R. M., Chandiwana, N. C., Chow, E. W. K., Franco, D. R., Halpern, B., Lamptey, R., Lingvay, I., Ma, R. C. W., Mohan, V., et al. (2026) · The Lancet Obstetrics Gynaecology & Women s Health · doi:10.1016/s3050-5038(26)00228-1
Erkan, İ. B. Ö., Senturk, L. M., Erel, C. T., Seyisoğlu, H., Şahmay, S., & Durmuşoğlu, F. (2026) · Climacteric · doi:10.1080/13697137.2026.2735765 · Cited by 1
Loss of Female Cardiovascular Protection in Diabetes: From Mechanisms to Intervention
Gady, J. P., Akter, S., VandeWiele, M., & Dong, F. (2026) · Cells · doi:10.3390/cells15211972
Metadata
- Authors
- Clemens, K. K., Woodward, M., Neal, B., & Zinman, B.
- Affiliations
- Western University (CA)
- Johns Hopkins University (US)
- The George Institute for Global Health (AU)
- Mount Sinai Hospital (CA)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-04-13
- Volume
- 43
- Issue
- 5
- Pages
- 1157-1163
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3016435336
- Cited by
- 70
- References
- 52
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 12 · 2023: 13 · 2022: 11 · 2021: 11 · 2020: 2
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Sex and Gender in Healthcare
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Social Sciences › Gender Studies › Diversity and Career in Medicine
- Keywords
- sex disparities, type 2 diabetes, cardiovascular outcome trials, major adverse cardiovascular events, cardiovascular risk factors, statins, aspirin, beta-blockers, stroke, heart failure, chronic kidney disease, HbA1c, LDL cholesterol, systolic blood pressure, women in clinical trials, sex differences in drug response
- MeSH terms
- Adolescent, Adrenergic beta-Antagonists, Adult, Aged, Aged, 80 and over, Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Diabetic Angiopathies, Female, Heart Failure, Glycated Hemoglobin, Humans, Male, Middle Aged, Sex Characteristics, Randomized Controlled Trials as Topic, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Renal Insufficiency, Chronic, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.